Xalkori Capsule
NDC 0069-8141
Product Information
Xalkori (crizotinib) is a NDA-approved product labeled by Pfizer Laboratories Div Pfizer Inc. Crizotinib is used to treat certain types of lung cancer. It is supplied as a pink capsule for oral administration. This product entry covers the primary NDC 0069-8141 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
WHITE (C48325 - OPAQUE)
19 MM
PFIZER;CRZ;250
PFIZER;CRZ;200
Code Structure Chart
Product Details
What is NDC 0069-8141?
What are the uses of this product?
What are Active Ingredients of this product?
- CRIZOTINIB 200 mg/1 - A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CRIZOTINIB (UNII: 53AH36668S)
- CRIZOTINIB (UNII: 53AH36668S) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- SHELLAC (UNII: 46N107B71O)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- AMMONIA (UNII: 5138Q19F1X)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1148498 - crizotinib 200 MG Oral Capsule
- RxCUI: 1148502 - Xalkori 200 MG Oral Capsule
- RxCUI: 1148502 - crizotinib 200 MG Oral Capsule [Xalkori]
- RxCUI: 1148504 - crizotinib 250 MG Oral Capsule
- RxCUI: 1148506 - Xalkori 250 MG Oral Capsule
Which are the Pharmacologic Classes of this product?
- Cytochrome P450 2B6 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- Kinase Inhibitor - [EPC] (Established Pharmacologic Class)
- Organic Cation Transporter 1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- Receptor Tyrosine Kinase Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Crizotinib
Crizotinib is used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is also used to treat a certain type of anaplastic large cell lymphoma (ALCL) that has returned or is unresponsive to other treatment(s) in certain adults and children 1 year of age and older. Crizotinib is also used to treat a certain type of inflammatory myofibroblastic tumor (IMT; type of cancer that occurs in mucosal tissues usually in the abdominal area, involving the lungs, bladder, stomach, uterus, liver, or intestines) that cannot be treated with surgery or that has not improved or has come back after previous treatment(s) in adults and children 1 year of age and older. Crizotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
[Learn More]
* Please review the full disclaimer at the bottom of this page.